News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium.



Website: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-001048,00.asp

Posted on: 06/08/2004

Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium.

Meeting: 2004 ASCO Annual Meeting

Category: Central Nervous System Tumors

SubCategory: CNS Tumors

Abstract No: 1541

Author(s): B. Neyns, E. Everaert, E. Joosens, T. Strauven, F. Branle, J. Menten; AZ-VUB, Brussels, Belgium; UZ KUL, Leuven, Belgium; AZ Middelheim, Antwerpen, Belgium; AZ Sint-Augustinus, Wilrijk, Belgium; Hôpital Erasme ULB, Brussels, Belgium

Abstract: Background: Temozolomide (TMZ) is an oral alkylating agent that has demonstrated objective activity and an acceptable toxicity profile for the treatment of recurrent high-grade gliomas in phase II trials. Only limited information is available on the activity and toxicity of TMZ when prescribed outside a clinical trial. Methods: We conducted a retrospective study to evaluate the activity and safety of TMZ that was prescribed for the treatment of recurrent glioma in the context of a compassionate use program in Belgium. Data were obtained on 117 adult patients (from 5 hospitals) who received TMZ as first or second line chemotherapy. The recommended starting dose of TMZ was 200 mg/m2 x5d q28d for chemonaïve patients and 150 mg/m2 x5d q28d for pretreated patients.

Results: Toxicity was generally mild although grade 3/4 toxicity was observed in 22 % of patients. Thrombocytopenia was the most frequent encountered toxicity (grade 3/4 in 17% of patients) and its occurrence was correlated with a starting dose of 200 mg/m²/d. The overall RR (CR + PR) was 29% and 34 % of patients achieved a SD. The median PFS was 104 days (95% CI 85-123) and the median OS was 215 days (95% CI 161-269). In multivariate analysis a “deep localization” of the glioma (as opposed to a cortico-subcortical localization) and the preceding history of a low-grade glioma were identified as independent prognostic variables with regard to TTP & OS. Administration of TMZ as first line chemotherapy was an independent prognostic variable for TTP only. Absence of disease progression at the end of TMZ cycle 3 was significantly correlated with a superior overall survival (landmark analysis, P<0.0001). Conclusions: This retrospective study indicates that the reported activity and toxicity profile of TMZ for the treatment of patients with recurrent glioma is reproducible outside the setting of a prospective clinical trial.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites